Welcome to the InfoSci Platform
Reference Hub2
Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Carlos Henrique Ferreira Camargo, Marcus Vinicius Della-Coletta, Delson José da Silva, Hélio A. G. Teive
Copyright: © 2019 |Pages: 24
ISBN13: 9781522552826|ISBN10: 1522552820|EISBN13: 9781522552833
DOI: 10.4018/978-1-5225-5282-6.ch013
Cite Chapter Cite Chapter

MLA

Camargo, Carlos Henrique Ferreira, et al. "Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy." Handbook of Research on Critical Examinations of Neurodegenerative Disorders, edited by Md. Sahab Uddin and Md. Shah Amran, IGI Global, 2019, pp. 274-297. https://doi.org/10.4018/978-1-5225-5282-6.ch013

APA

Camargo, C. H., Della-Coletta, M. V., José da Silva, D., & Teive, H. A. (2019). Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy. In M. Uddin & M. Amran (Eds.), Handbook of Research on Critical Examinations of Neurodegenerative Disorders (pp. 274-297). IGI Global. https://doi.org/10.4018/978-1-5225-5282-6.ch013

Chicago

Camargo, Carlos Henrique Ferreira, et al. "Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy." In Handbook of Research on Critical Examinations of Neurodegenerative Disorders, edited by Md. Sahab Uddin and Md. Shah Amran, 274-297. Hershey, PA: IGI Global, 2019. https://doi.org/10.4018/978-1-5225-5282-6.ch013

Export Reference

Mendeley
Favorite

Abstract

Alpha-synuclein is a protein that forms a major component of abnormal neuronal aggregates known as Lewy bodies. A particular group of neurodegenerative disorders (NDs) is characterized by the abnormal accumulation of α-synuclein; termed the α-synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lysosomal storage diseases have also been linked to α-synuclein toxicity. Several therapeutic targets have been chosen among steps of metabolism of α-synuclein. Reducing α-synuclein synthesis or expression and increasing the clearance can be achieved in many ways. The development of immunotherapeutic approaches targeting α-synuclein has received considerable attention in recent years. The aim of this chapter is to present the α-synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α-synuclein pathways.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.